1. 1.科研項(xiàng)目 結(jié)題:山西省重點(diǎn)研發(fā)計(jì)劃(國際科技合作)項(xiàng)目 項(xiàng)目編號(hào)201903D421072 ,項(xiàng)目起止日期:201903D421072 項(xiàng)目名稱:臭氧通過誘導(dǎo)氣道上皮細(xì)胞產(chǎn)生ATP激活肥大細(xì)胞加重哮喘發(fā)病機(jī)制的研究 資助10萬 在研:國家自然科學(xué)基金面上項(xiàng)目,項(xiàng)目批準(zhǔn)號(hào)82370024,項(xiàng)目起止日期:2021年1月-2027年12月 資助經(jīng)費(fèi)49萬 項(xiàng)目名稱:臭氧介導(dǎo)KDM5C/METTL14/NLRP3降解GRα促進(jìn)激素抵抗性哮喘的機(jī)制研究 2. 2.文章 1)Identification of an ATP/P2X7/mast cell pathway mediating ozone-induced bronchial hyperresponsiveness. JCI Insight. 2021 Nov 8;6(21):e140207. doi: 10.1172/jci.insight.140207. 2) Lactobacillus fermentum CECT5716 Alleviates the Inflammatory Response in Asthma by Regulating TLR2/TLR4 Expression. Front Nutr. 2022 Jul 14;9:931427. doi: 10.3389/fnut.2022.931427. PMID: 35911120; PMCID: PMC9331901. 3) ESR2 regulates PINK1-mediated mitophagy via transcriptional repression of microRNA-423 expression to promote asthma development. Pharmacol Res. 2021 Dec;174:105956. doi: 10.1016/j.phrs.2021.105956. Epub 2021 Oct 23. PMID: 34700017. 4)Analysis of COVID-19 epidemic and clinical risk factors of patients under epidemiological Markov model. Results Phys. 2021 Mar;22:103881. doi: 10.1016/j.rinp.2021.103881. Epub 2021 Feb 4. PMID: 33558843; PMCID: PMC7857990.Biotechnol. 2024 Jan;17(1):e14364. doi: 10.1111/1751-7915.14364. Epub 2023 Nov 6. PMID: 37929823; PMCID: PMC10832515. 5.發(fā)明專利:一種具有臭氧發(fā)生功能的智能化培養(yǎng)設(shè)備2014年2月已通過初審 6.學(xué)術(shù)任職:中華醫(yī)學(xué)會(huì)呼吸病學(xué)分會(huì)呼吸治療學(xué)組委員、中國老年保健醫(yī)學(xué)研究會(huì)呼吸病學(xué)分會(huì)委員、山西臨床流行病學(xué)和循證醫(yī)學(xué)委員、山西省醫(yī)師協(xié)會(huì)哮喘學(xué)組副主任委員、山西省女醫(yī)師協(xié)會(huì)理事 |